SUTRO BIOPHARMA, INC. Quarterly Debt-to-equity in % from Q2 2019 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Sutro Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q2 2019 to Q2 2024.
Sutro Biopharma, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 250 %, a 134% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	250	+143	+134%	Jun 30, 2024
Q1 2024	244	+160	+189%	Mar 31, 2024
Q4 2023	187	+116	+163%	Dec 31, 2023
Q3 2023	148	+91.2	+160%	Sep 30, 2023
Q2 2023	107	+62	+137%	Jun 30, 2023
Q1 2023	84.4	+55.1	+188%	Mar 31, 2023
Q4 2022	70.8	+46.5	+191%	Dec 31, 2022
Q3 2022	57	+36.4	+177%	Sep 30, 2022
Q2 2022	45.2	+26	+136%	Jun 30, 2022
Q1 2022	29.4	+6.68	+29.5%	Mar 31, 2022
Q4 2021	24.4	-6.61	-21.4%	Dec 31, 2021
Q3 2021	20.6	-21.3	-50.8%	Sep 30, 2021
Q2 2021	19.2	-33.8	-63.7%	Jun 30, 2021
Q1 2021	22.7	-41.2	-64.5%	Mar 31, 2021
Q4 2020	31	-26.1	-45.8%	Dec 31, 2020
Q3 2020	41.9	-18	-30%	Sep 30, 2020
Q2 2020	53	-85.1	-61.6%	Jun 30, 2020
Q1 2020	63.9			Mar 31, 2020
Q4 2019	57.1			Dec 31, 2019
Q3 2019	59.9			Sep 30, 2019
Q2 2019	138			Jun 30, 2019

* An asterisk sign (*) next to the value indicates that the value is likely invalid.